EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost‐Effectiveness of Treating Hepatitis C in Clients on Opioid Agonist Therapy in Community Pharmacies Compared to Primary Healthcare in Australia

Joshua F Ginnane iD, Nick Scott iD, Andrew Radley, John F Dillon, Margaret Hellard iD, Joseph Doyle

Journal of Viral Hepatitis · 2025

DOI: 10.1111/jvh.14015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Viral Hepatitis, 2025. Verfasst von Joshua F Ginnane und 5 weiteren Autor:innen. Beteiligte Einrichtung: Disease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Primary Health Care, Hepatitis C, Analgesics, Opioid, Opiate Substitution Treatment. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Government, Community Grants Hub, Australian Government.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Meeting the World Health Organisation 2030 target of treating 80% of people with hepatitis C virus (HCV) in Australia requires accessible testing and treatment services for at‐risk populations. Previous clinical trials, including those in Australia, have demonstrated the efficacy of outreach programmes to community pharmacies offering opioid agonist therapy (OAT). This analysis evaluates the potential cost‐effectiveness of introducing an outreach programme in community pharmacies. Using a decision analytic model, we estimated the impact of adding a temporary hepatitis C outreach and treatment programme in community pharmacies to the standard treatment pathway available through general practice. We compared the expected number of tests, diagnoses, cures and costs occurring through the addition of this outreach and treatment programme to those expected through general practice alone over a 12‐month time horizon. We examined costs from the perspective of the health system and conducted one‐way and probabilistic sensitivity analyses to assess uncertainty in model parameters and test key assumptions. In the model adding the outreach programme pathway increased the number of tests from 4178 to 8737, the number of diagnoses from 615 to 1285 and the number of cures from 223 to 777 among people on OAT over a 12‐month period. Each additional cure achieved through the addition of the outreach programme was estimated to incur $48,964 (AUD 2023) to the health system, with > 85% of these costs attributable to medication and dispensing expenses. The average cost per cure was estimated to be $49,152 through routine care and $49,018 in the outreach programme. Although outreach models of care incur large upfront costs, they can capture otherwise unreached populations and result in comparable or favourable cost per cure, due to higher levels of engagement and lower rates of loss to follow‐up.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Primary Health CareHepatitis CAnalgesics, OpioidOpiate Substitution TreatmentHumansAustraliaCost-Benefit AnalysisPharmaciesAntiviral AgentsMaleFemale

Stichwörter der Autor:innen

cost‐effectiveness analysishepatitis Copiate substitution treatmentpharmacies

Substanzen

Analgesics, OpioidAntiviral Agents

Autor:innen und Institutionen

  • Disease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia.
  • School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
  • Division of Molecular and Clinical Medicine, University of Dundee, Dundee, UK.
  • Directorate of Public Health, Kings Cross Hospital, NHS Tayside, Dundee, UK.
  • Department of Gastroenterology, Ninewells Hospital and Medical School, NHS Tayside, Dundee, UK.
  • Department of Infectious Diseases, Alfred Health and Monash University, Melbourne, Victoria, Australia.

ORCID-Profile: Joshua F Ginnane, Nick Scott, Margaret Hellard

Förderung

  • Australian Government, Community Grants Hub
  • Australian Government

Zitieren

APA

Ginnane, J. F., Scott, N., Radley, A., Dillon, J. F., Hellard, M., & Doyle, J. (2025). Cost‐Effectiveness of Treating Hepatitis C in Clients on Opioid Agonist Therapy in Community Pharmacies Compared to Primary Healthcare in Australia. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.14015

Vancouver

Ginnane JF, Scott N, Radley A, Dillon JF, Hellard M, Doyle J. Cost‐Effectiveness of Treating Hepatitis C in Clients on Opioid Agonist Therapy in Community Pharmacies Compared to Primary Healthcare in Australia. Journal of Viral Hepatitis. 2025. doi:10.1111/jvh.14015

BibTeX
@article{Ginnane2025,
  author = {Ginnane, Joshua F and Scott, Nick and Radley, Andrew and Dillon, John F and Hellard, Margaret and Doyle, Joseph},
  title = {Cost‐Effectiveness of Treating Hepatitis C in Clients on Opioid Agonist Therapy in Community Pharmacies Compared to Primary Healthcare in Australia},
  journal = {Journal of Viral Hepatitis},
  year = {2025},
  doi = {10.1111/jvh.14015}
}
Kostenlos starten →